Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chlortetracycline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | THRB | P10828 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.71 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.71 |
| ▸ | PDE4A | P27815 | 1/20 | 0.71 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 10/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.70 |
| ▸ | USP2 | O75604 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chlortetracycline SCHEMBL19787489 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3110 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL27323552 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL5503038 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL10901448 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL12356689 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782583 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL13782533 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL20952683 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB | |
| Chlortetracycline SCHEMBL3111 | 1.00 | MAPT (0.71) | MAPTHSD17B10GAALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. | 2018-01-18 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | PARATEK PHARMACEUTICALS, INC. (US) | 2015-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016225-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | MAPT 823/4885HSD17B10 1112/4885GAA 41/4885 |
| US-20150141381-A1 | TETRACYCLINE COMPOUNDS HAVING TARGET THERAPEUTIC ACTIVITIES | TBCA, TUBB6, TUBB | MAPT 823/4885HSD17B10 1112/4885GAA 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.